Marcio Augusto Diniz
Overview
Explore the profile of Marcio Augusto Diniz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caceres N, Yu Q, Capaldi J, Diniz M, Raynor H, Foster G, et al.
Contemp Clin Trials
. 2022 Jul;
119:106844.
PMID: 35798248
Background: Although many people try to lose weight, a large proportion of individuals do not achieve clinically significant weight loss. Nonresponse and relapse rates in lifestyle interventions are largely explained...
2.
Diniz M
J Nucl Cardiol
. 2022 May;
29(6):3248-3255.
PMID: 35610537
Predictive models are widely used in clinical practice. Despite of the increasing number of published AI systems, recent systematic reviews have identified lack of statistical rigor in the development and...
3.
Iribarren A, Diniz M, Merz C, Shufelt C, Wei J
Contemp Clin Trials
. 2022 Apr;
117:106762.
PMID: 35460916
Despite calls to ensure proportionate representation of both sexes in biomedical research, women continue to be underrepresented in cardiovascular disease (CVD) clinical trials. A comprehensive analysis of seven large suspected...
4.
Wu J, Raz Y, Recouvreux M, Diniz M, Lester J, Karlan B, et al.
Front Oncol
. 2022 Apr;
12:853755.
PMID: 35387127
Objective: Serous tubal intra-epithelial carcinoma (STIC) lesions are thought to be precursors to high-grade serous ovarian cancer (HGSOC), but HGSOC is not always accompanied by STIC. Our study was designed...
5.
Crescente J, Dellavance A, Diniz M, Carrilho F, Andrade L, Cancado E
Clinics (Sao Paulo)
. 2021 Feb;
76:e2228.
PMID: 33567045
Objectives: To determine the frequency of the antineutrophil cytoplasmic antibodies (ANCA), antiproteinase-3 and antimyeloperoxidase, in primary sclerosing cholangitis (PSC) with or without inflammatory bowel disease (IBD+ or IBD-) and in...
6.
Silva M, Diniz M, Carvalho R, Chiba T, Mattos-Pimenta C
Rev Bras Enferm
. 2020 Aug;
73(6):e20190391.
PMID: 32785516
Objective: To compare the relief of symptoms provided by palliative care consultation team (PCCT) compared to the traditional care team (TC), in patients with advanced cancer in the first 48...
7.
Diniz M, Kim S, Tighiouart M
J Probab Stat
. 2019 Mar;
2018.
PMID: 30906326
A Bayesian adaptive design for dose finding of a combination of two drugs in cancer phase I clinical trials that takes into account patients heterogeneity thought to be related to...
8.
Diniz M, Tighiouart M, Rogatko A
PLoS One
. 2019 Jan;
14(1):e0210139.
PMID: 30625194
Despite of an extensive statistical literature showing that discretizing continuous variables results in substantial loss of information, categorization of continuous variables has been a common practice in clinical research and...
9.
Terrabuio D, Diniz M, Falcao L, Guedes A, Nakano L, Evangelista A, et al.
Hepatol Commun
. 2019 Jan;
3(1):116-128.
PMID: 30619999
Between 50% and 86% of patients with autoimmune hepatitis (AIH) relapse after immunosuppression withdrawal; long-term immunosuppression is associated with increased risk of neoplasias and infections. Chloroquine diphosphate (CQ) is an...
10.
Diniz M, Quanlin-Li , Tighiouart M
J Biom Biostat
. 2018 Mar;
8(6).
PMID: 29552377
We describe a dose escalation algorithm for drug combinations in cancer phase I clinical trials. Parametric models for describing the association between the doses and the probability of dose limiting...